Literature DB >> 11986403

A 39-bp deletion polymorphism in PTEN in African American individuals: implications for molecular diagnostic testing.

Xiao-Ping Zhou1, Heather Hampel, Jennifer Roggenbuck, Nabil Saba, Thomas W Prior, Charis Eng.   

Abstract

Germline mutations in the PTEN/MMAC1/TEP1 tumor suppressor gene cause Cowden syndrome (CS), a hereditary hamartoma-tumor syndrome with an increased risk of breast, thyroid, and endometrial cancers, and seemingly unrelated developmental disorders, such as Bannayan-Riley-Ruvalcaba (BRR) syndrome, Proteus, and Proteus-like syndromes. Data to date suggest that irrespective of the clinical presentation, the identification of a PTEN mutation should trigger medical management which includes cancer surveillance. Clinic-based molecular diagnostic testing for germline PTEN mutations has been available for at least 2 years. This study reports on the finding of a previously unobserved heterozygous alteration (IVS7-15-->53del39) found in an African American individual who had features of CS. Further investigation revealed that 12 of 42 (28.6%) African American controls, but not individuals of Caucasian or Japanese origin, also carried this heterozygous 39-bp deletion in PTEN. Due to its location immediately upstream of the splicing site of exon 8, this polymorphism could be mistaken for a deleterious mutation in the PTEN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986403      PMCID: PMC1906990          DOI: 10.1016/S1525-1578(10)60690-3

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  26 in total

1.  Will the real Cowden syndrome please stand up: revised diagnostic criteria.

Authors:  C Eng
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

2.  Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death.

Authors:  L P Weng; O Gimm; J B Kum; W M Smith; X P Zhou; D Wynford-Thomas; G Leone; C Eng
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

3.  PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways.

Authors:  L Weng; J Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

4.  PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.

Authors:  L P Weng; J L Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

5.  PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.

Authors:  L P Weng; W M Smith; J L Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

6.  Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.

Authors:  X P Zhou; D J Marsh; H Hampel; J B Mulliken; O Gimm; C Eng
Journal:  Hum Mol Genet       Date:  2000-03-22       Impact factor: 6.150

7.  Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes.

Authors:  X Zhou; H Hampel; H Thiele; R J Gorlin; R C Hennekam; M Parisi; R M Winter; C Eng
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

8.  PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.

Authors:  L P Weng; W M Smith; P L Dahia; U Ziebold; E Gil; J A Lees; C Eng
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

9.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

10.  Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer.

Authors:  Q Gao; G Tomlinson; S Das; S Cummings; L Sveen; J Fackenthal; P Schumm; O I Olopade
Journal:  Hum Genet       Date:  2000-08       Impact factor: 4.132

View more
  1 in total

1.  An intronic polymorphic deletion in the PTEN gene: implications for molecular diagnostic testing.

Authors:  S Sandell; R J L Schuit; D J Bunyan
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.